

Press Release

Bangalore, October 24, 2011

Strides delivers Superior Q3 '2011 Financials Ups Full Year Guidance

Revenue up by 81 %

Rs.780 Crores against Rs. 430 Crores in Q3 '2010

EBITDA up by 73%

Rs.153 Crores against Rs.88 Crores in Q3 '2010

PAT up by 34%

Rs.47 Crores against Rs. 35 Crores in Q3 '2010

(Source: Unaudited consolidated results for Q3'2011)


Highlights:

- Q3'11 EBITDA at Rs. 153 Crores - up by 73%, EBITDA adjusted for forex loss of Rs. 30 Crores, at Rs. 182 Crores, up by 106%
- Q3'11 PAT at Rs 47 Crores - up by 34%, (inspite of adverse forex impact to the tune of Rs 58 Crores for the quarter)
- Licensing Income exceeds full year guidance, on account of new licensing transactions in the Pharma business
 - 47 filings and 42 approvals from key regulated markets and 40 filings and 29 approvals from key emerging markets
 - 14 products approved by US FDA (total US FDA approvals at 74)
 - 7 product approvals from EU (total EU approvals at 16)

Guidance:

- Revenue guidance revised upwards from Rs 2200 Crores to Rs 2500 Crores
- EBITDA to exceed Rs. 480 Crores

A detailed analysis of the results is appended as an attachment to this press release.



“I am glad that the business is tracking ahead of guidance in spite of a difficult macroeconomic environment, particularly in relation to volatile currencies in the key markets we operate. With continued momentum of new product launches and approvals in our specialties business, I am confident of continued operating performance scale up in the coming quarters” said Arun Kumar, Vice Chairman & Group CEO, Strides Arcolab Limited.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India, that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the Company’s website at www.stridesarco.com.

For further information, please contact:

<p><u>Strides</u></p> <p>Dr. T.S. Rangan, Group CFO +91 80 6784 0115</p> <p><u>Investors:</u></p> <p>Mr. Kannan. N: +91 98450 54745 Mr Ajay Singh: +91 80 6784 0813</p>	<p><u>PR Consultancy</u></p> <p>Corporate Voice/Weber Shandwick</p> <p>Mahesh Nair: +91 98803 76648 maheshn@corvoshandwick.co.in</p> <p>Hiba Kunil: +91 98807 26372 hiba@corvoshandwick.co.in</p>
---	--

